Partners

  • Robert A. Ingram

    General Partner

    robert-ingram

    Bob Ingram joined the firm of Hatteras Venture Partners as a General Partner on January 24, 2007. Hatteras Venture Partners is a venture capital firm that invests in early stage life science companies in the southeast United States.

    Bob began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become CEO/Chairman of GlaxoWellcome. He co-led the merger and integration that formed GlaxoSmithKline, the world’s second largest pharmaceutical company. Upon reaching the mandatory retirement age of 60, he was asked by the Board to serve as Vice Chairman Pharmaceuticals, GSK, which he did until January 1, 2010, at which time he became Strategic Advisor to the Chief Executive Officer, GlaxoSmithKline plc.

    He serves as Lead Director of Valeant Pharmaceuticals International and Cree, Inc. He is also a member of the Board of Directors of Edwards Lifesciences Corporation.

    In addition to his professional responsibilities, Bob was asked by former US President George H.W. Bush to form and chair the CEO Roundtable on Cancer. He is a member of numerous other civic and professional organizations. In January 2004, Bob was awarded the Martin Luther King, Jr. Legacy Award for International Service. On July 27, 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board.

    Bob is a member of the Boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, H. Lee Moffitt Cancer Center, CEO Roundtable on Cancer, Research Triangle Institute and Chairman, GlaxoSmithKline Foundation. He serves as Chairman of Research Triangle Foundation of North Carolina and is on the Advisory Board, Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California.

    Bob graduated from Eastern Illinois University with a BS degree in Business Administration.

  • Kenneth B. Lee, Jr.

    General Partner

    Kenneth B. Lee

    Kenneth B. Lee, Jr. is involved in deal sourcing, investment decisions and implementing exit strategies as a general partner of HVP III. He is also a general partner for HVP II, where he has played an important role in deal sourcing, syndication and management recruitment, and evaluation. Ken is the former co-head of International Life Sciences for Ernst & Young, where he established a career over 29 years advising biotechnology and pharmaceutical companies throughout the world.

    He got his start in biotech as part of the first audit team of Genentech in 1976. As co-founder and manager of the firm’s national life sciences practice from his location in the San Francisco Bay Area, he advised numerous high profile life science companies with their initial public offerings, mergers and acquisitions, and strategic financings. Among others, these included: Affymax, Affymetrix, Applied ImmuneSciences, Chiron, Circadian, Genentech, Heartport, Systemix, ALZA, and Collagen.

    Ken serves on the Board of Directors of Clinverse, and is Chairman of the Board of Clinipace. He graduated with a BA from Lenoir-Rhyne College and has an MBA from the University of North Carolina at Chapel Hill.

    Community and Board Engagements:

    Ken is a nationally-recognized financial matters expert and serves on the boards of Maxygen, Inc. (MAXY), Pozen, Inc. (POZN) and Biocryst. He was formerly Chairman of the Board of Inspire Pharmaceuticals, Inc. (ISPH), prior to the sale of the company. Until April 2009, Ken was also on the board of CV Therapeutics, which was acquired by Gilead Sciences, Inc.

  • Douglas Reed, MD

    General Partner

    Douglas Reed, MD

    Doug joined Hatteras Venture Partners as a General Partner in early 2007. He has 19 years of venture investment experience between Hatteras and his two prior healthcare-focused venture firms, Vector Fund Management and S.R. One. He has also spent part of his career in operating roles as VP of Business Development for two biotechnology companies, NPS Pharmaceuticals and subsequently, GelTex Pharmaceuticals (acquired by Genzyme).

    At Hatteras, Doug focuses on investments in the bio-pharmaceutical and medical technology fields. He currently serves as Chairman of the Board of Viamet Pharmaceuticals and is also a director of Coferon, SpineAlign Medical, and TetraLogic Pharmaceuticals. He was a director of Embrella Cardiovascular prior to its sale to Edwards Lifesciences.

    Doug earned a BA in biology and an MD from the University of Missouri in Kansas City. He completed his residency in diagnostic radiology at the University of Washington and a fellowship in neuro-radiology at the University of British Columbia. After stints on the faculty in the Department of Radiology at the University of Washington and at Yale University he earned an MBA from the Wharton School at the University of Pennsylvania.

    Community and Board Engagements:

    Doug serves on the board of SEBIO, the Southeastern Biotechnology Organization and on the National Board of Visitors of his alma mater the University of Missouri – Kansas City School of Medicine.

  • Clay B. Thorp

    General Partner

    Clay B. Thorp

    Clay is an entrepreneur turned venture capitalist. Since 1995, Clay has co-founded seven companies in the life science arena and co-founded Hatteras in 2001. Since co-founding Hatteras, Clay has been instrumental in building the firm and has led investments in a range of life science companies, including biopharmaceutical, medical device, diagnostics, and research informatics.

    Clay was the lead investor and led the strategic transaction process for ArtusLabs that resulted in its sale to PerkinElmer in 2011. He was a co-founder and served as CEO and Chairman of Synthematix, Inc., a chemistry informatics company that was acquired in April 2005 by Symyx Technologies (SMMX). Clay is a co-founder and former Chairman of PhaseBio Pharmaceuticals, Inc. He was the co-founder and head of corporate development for Novalon Pharmaceutical Corporation, where he led financing efforts and was head of business development from inception until Novalon’s sale to Karo Bio in May of 2000. Prior to Novalon, Clay was the co-founder and president of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins.

    Clay currently serves as Chairman of GeneCentric Diagnostics and Lead Director of Pathfinder Therapeutics. He is also on the boards of PhaseBio Pharmaceuticals, Clearside Biomedical, and G1 Therapeutics. He holds a Masters of Public Policy from Harvard University and a B.A. in mathematics and history from the University of North Carolina at Chapel Hill.

    Community and Board Engagements:

    Clay started his career as a social entrepreneur by co-founding the Student Coalition for Action in Literacy Education (SCALE) as a junior at UNC-Chapel Hill in 1989. For that, he was honored as Point of Light by George H.W. Bush. Since that time, Clay has been active at state and national levels in public policy and public service. He is a past board member of the NC Biotechnology Center, CED, Public Allies, and the Wildacres Leadership Initiative. He currently serves on the Board of Trustees of the NC Supplemental Retirement System and the NC BioFuels Center. Clay is also a member of the Foundation Board of the NC School of Science and Mathematics.

  • John Crumpler

    General Partner

    John Crumpler

    John co-founded Hatteras in 2000 after a successful career as a technology entrepreneur. At Hatteras, John is responsible for the firm’s investments in healthcare and life science information technology, and overall fund operations. He was founder and CEO of E-Comm, Inc., a software development and services firm specializing in remote and mobile computing that was acquired by XcelleNet. John ran the services division of XcelleNet until the company was acquired by Sterling Commerce.

    John served on the board of Synthematix and currently serves on the boards of Clinipace Worldwide, where he has helped lead the transformation of Clinipace from a pure software company to a full-service digital CRO, and Clinverse, an IT company focused on the financial management of clinical trials. He holds an A.B. from Harvard University.

    Community and Board Engagements:

    Throughout his career John has been active in government and public policy at the state and federal levels. A recipient of the Lyndhurst Prize, John served on the N. C. Economic Development Board, the state’s Clean Water Management Trust Fund board of directors, and as a trustee of the University of North Carolina School of the Arts. He currently serves on the board of the Council for Entrepreneurial Development and as a director of SouthLight, Inc.